Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887622 · ClinicalTrials.gov registry record · NA
The Potassium Supplementation Study
A NA study of Cardiovascular Risk Factor and Cardiovascular Health, sponsored by University of Delaware.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05887622: Recruiting NA study of Cardiovascular Risk Factor and Cardiovascular Health, sponsored by University of Delaware.
NCT05887622 is a NA study of Cardiovascular Risk Factor and Cardiovascular Health that is actively recruiting participants, run by University of Delaware. The registered enrollment target is 30 participants, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05887622, a NA study of Cardiovascular Risk Factor and Cardiovascular Health, is actively recruiting participants, sponsored by University of Delaware.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether potassium supplementation can reduce the deleterious effect of a high sodium diet on blood vessel function, blood pressure reactivity and autonomic nervous system function in apparently healthy adults.
Primary Outcome
The difference in flow-mediated dilation (FMD) between the 3 diets
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Potassium chloride supplement
Study Locations (1)
Delaware
- Tower at STAR - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2026-01-31 |
| Phase | NA |
What NCT05887622 shows while recruiting
NCT05887622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05887622 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT05887622 about?
NCT05887622 is a clinical study titled "The Potassium Supplementation Study". This study will test whether potassium supplementation can reduce the deleterious effect of a high sodium diet on blood vessel function, blood pressure reactivity and autonomic nervous system function in apparently healthy adults.
What is the current status of trial NCT05887622?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-01-24. Estimated completion is 2026-01-31.
What conditions does trial NCT05887622 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor, Cardiovascular Health.
What interventions are being tested in trial NCT05887622?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Potassium chloride supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05887622?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887622 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05887622's enrollment target sits among peer trials
30 25th of 31 higher than 6 of 31 other Cardiovascular Risk Factor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Risk Factor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
RECRUITING · NA
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans
RECRUITING · NA
-
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
ACTIVE NOT RECRUITING · NA
-
Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI